HD-OPM Archive
Topics › Inflammation & CRP

Medscape news: FDA approves low-dose colchicine for broad cardiovascular use

Gokhan Can · Dec 24, 2023 · ♥ 20 reactions · 44 comments · original Facebook post
Inflammation & CRPAspirin, antiplatelets & blood thinners
AI summary & key facts

Links a Medscape report on FDA approval of low-dose colchicine for a broad cardiovascular indication, with a note that the approval extends to primary prevention in people with multiple risk factors. No specific trial is described in the post.

Please note that the drug has been approved even for primary prevention with multiple risk factors.

MedscapeFDA OKs Low-Dose Colchicine for Broad CV IndicationThe drug represents the first specific anti-inflammatory drug for the reduction of cardiovascular events for patients with established atherosclerotic disease or with multiple risk factors.medscape.com
#riskfactors#colchicine#cardiovascular#prevention
← newer: SELECT trial: semaglutide cut major cardiovascular events 20older: Discussion prompt: small changes to reduce cardiovascular ri →